
    
      CC-10004 is a well-tolerated, selective PDE4 inhibitor with a demonstrated inhibitory effect
      on inflammatory mediators and is under development for the treatment of inflammatory and
      immune mediated conditions.

      This is an open-label, one arm, phase II study at William Beaumont Hospital. Twenty female
      subjects aged 18 or older meeting criteria for diagnosis of vulvodynia or vulvar vestibulitis
      (vestibulodynia) will be treated with CC-10004 at 20mg orally twice a day for 12 weeks.The
      patient will be seen for a total of ten visits by the study coordinator.
    
  